Mobile App Intervention for Childhood-Onset Lupus
(ECHOS Trial)

Recruiting in Palo Alto (17 mi)

Overseen byTamar B Rubinstein, MD, MS

Age: < 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Montefiore Medical Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial aims to see if a custom mobile app can help young people with lupus stay engaged in their medical care and manage depression. The study focuses on adolescents and young adults from the Bronx, ages 15-24. The app offers personalized support to help them keep up with health appointments and improve their mood.

Research Team

Tamar B Rubinstein, MD, MS

Principal Investigator

Montefiore Medical Center

Eligibility Criteria

This trial is for young individuals aged 15-24 in the Bronx, NY with childhood-onset systemic lupus erythematosus (cSLE). They must meet specific lupus criteria and have been diagnosed before age 19. It's not for those who don't speak English or Spanish, plan to change rheumatologists soon, or have current psychotic disorders.

Inclusion Criteria

I was diagnosed with lupus before I turned 19.

I am 15-24 years old with diagnosed lupus and treated at the Children's Hospital at Montefiore.

Exclusion Criteria

I do not speak Spanish or English.

Participants anticipating transitioning to an outside rheumatologist for lupus care within the period of study follow-up

I do not have a current psychotic disorder but may have ADHD, anxiety, OCD, PTSD, an eating disorder, or a history of substance abuse or depression.

Treatment Details

Interventions

Valera Smart Phone Application (Behavioral Intervention)

Trial OverviewThe study is testing a mobile health app designed to help adolescents and young adults with lupus manage depression symptoms and improve engagement in their healthcare. Participants will use the app for six months while completing questionnaires about their experience.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Valera Pilot StudyExperimental Treatment1 Intervention

All participants in the open-label pilot study will be provided with the Valera smart phone application and online care manager dashboard